药品信息:
Glyxambi® (empagliflozin/linagliptin) 片剂由处方现在是可用的在美国的许多主导的链和独立药房，包括 Walgreens 和礼拜式帮助。 GLYXAMBI，一部分的 Boehringer Ingelheim Pharmaceuticals， Inc. (BIPI) 和 Eli 莉莉和公司 (NYSE ： LLY) 糖尿病联盟投资组合，是在美国和双重抗化剂组合疗法审批的仅第一个结合钠葡萄糖共同运输者 2 (SGLT2) 抗化剂和一种 dipeptidyl 肽酶4 (DPP-4) 抗化剂的活动结构在一种曾经每日片剂。
当 empagliflozin 和 linagliptin 是适当的处理， GLYXAMBI 被审批，因为附属节食和执行 (T2D)改进在成人的糖血症控制与第二类型糖尿病。 GLYXAMBI 是结合 10 毫克或 25 empagliflozin 毫克的早晨采取的一种曾经每日片剂，一种 SGLT2 抗化剂，与 5 linagliptin 毫克， DPP-4 抗化剂。 GLYXAMBI 不是为有第一类型糖尿病的人或为糖尿病酮酸中毒 (在血液或尿的增加的酮)。 如果您有胰腺炎 (胰腺的炎症) 不知道您是否有获得胰腺炎的一个更高的机会，当采取 GLYXAMBI 时。
“按照其最近粮食与药物管理局审批的 GLYXAMBI 的迅速市场可用性在 1月下旬是 Boehringer Ingelheim 的反映，并且对带来新的处理选项的 Lilly 的承诺给有第二类型糖尿病的人”，在美国卡特勒恩 Dowd，资深副总裁，营销， Boehringer Ingelheim Pharmaceuticals， Inc. 说 “作为第四糖尿病医学涌现从我们的联盟传递途径，我们相信 GLYXAMBI 可能帮助与低第二类型糖尿病的成人他们的血糖和管理他们的糖尿病”。
GLYXAMBI 储蓄卡程序是可以在网上进行和在合格的患者的许多医生的办公室。 对于条款和条件和任何问题关于适用性或福利，请参观 GLYXAMBIsavings.com 或叫 1-855-GLYXAMBI (1-855-459-9262)。
不应该采取 GLYXAMBI，如果您有严重肾脏问题，在透析或，如果您是过敏对 empagliflozin 和 linagliptin 或者其中任一在 GLYXAMBI 的成份。 严重的过敏反应的症状对 GLYXAMBI 的可能包括皮疹，发痒，剥落或者剥皮; 在您的皮肤 (项) 的被上升的红色补丁程序; 呼吸的困难吞下或; 或者可能造成吞下的困难呼吸或您的表面、嘴唇、舌头和喉头的膨胀。 如果您有这些症状中的任一种，请停止采取 GLYXAMBI 并且告诉您的医生或立即去这间急救室。
“作为对 metformin 的一个附加程序， GLYXAMBI 是优越在减少 A1C 与或者 empagliflozin 比较或单独 linagliptin”， Lilly 糖尿病说大卫肯德尔， M.D.，副总统，医疗事物。 “第二类型糖尿病的管理要求一个个性化的处理计划，并且 GLYXAMBI 提供患者和他们的医师以一个新的选项帮助改进血糖控制”。
美国食品药品监督管理局审批在评估效力和安全性 GLYXAMBI 的第III阶段临床试验基础上 (10/5 毫克和 25/5 毫克) 比较各自的要素 empagliflozin (10 毫克或 25 毫克) 或 linagliptin (5 毫克) 在与 T2D 的成人也采取高剂量 metformin (平均剂量 1889 毫克日报)。 研究，随机化与 T2D 和血红蛋白 A1C (平均血糖评定的 686 个成人在过去二个到三个月期间) 在 7.0 和 10.5% 之间，检查从草拟的变化在 A1C 上在 24 个星期。 研究展示了与 GLYXAMBI 的优越 A1C 减少比较 empagliflozin 或 linagliptin 各自的要素。 从大约 8.0% 开始平均草拟，在此试算的成人，分别，达到 6.9 和 6.7% 平均 A1C 与 GLYXAMBI 10/5 毫克的和 25/5 毫克比较 7.3 和 7.4% 和 25 毫克，分别和 linagliptin 5 毫克的 7.3% 平均 A1C empagliflozin 10 毫克的。
在糖尿病关心最近发布的数据展示了该 58% 和采取 GLYXAMBI 10/5 毫克或 25/5 毫克的 62% 的患者，除 metformin 之外达到少于从草拟大约 8% A1C 的 7% A1C，比较采取 empagliflozin 10 毫克的 28% 的患者， 33% 采取 empagliflozin 25 毫克的和采取 linagliptin 5 毫克的各自 36%。
通过 52 个星期， GLYXAMBI 安全轮廓在一个合并的分析被展示了，并且最公用的相反回应是尿道感染 (UTI) (12.5% 和 11.4% GLYXAMBI 10/5 毫克和 25/5 毫克的，分别; 通过 52 个星期，没有患者被中断的 GLYXAMBI 由于 UTIs)， nasopharyngitis (5.9% 和 6.6% GLYXAMBI 10/5 毫克和 25/5 毫克的，分别) 和上面的呼吸道传染 (7.0% GLYXAMBI 10/5 毫克和 25/5 毫克的)。
严重的副作用可能发生在采取 GLYXAMBI，包括胰腺 (胰腺炎) 的炎症的人身上，可能是严重的和导致死亡。 在您开始采取 GLYXAMBI 前，请告诉您的医生，如果您有胰腺炎、胆结石、酒精中毒的历史记录或者高的甘油三酸酯水平。 请停止采取 GLYXAMBI 并且立即告诉您的医生，如果您有痛苦在是严重的，并且不会消失的您的胃区 (腹部)。 痛苦可能感觉去从您的腹部到您的返回。 痛苦可能发生有或没有呕吐。 这些可能是胰腺炎的症状。
什么是 GLYXAMBI ？
GLYXAMBI 是包含 2 糖尿病医学、 empagliflozin 和 linagliptin 的处方医学。 当与 empagliflozin 和 linagliptin 的处理是适当的时， GLYXAMBI 可以用于以及饮食和执行降低在成人的血糖与第二类型糖尿病。
Glyxambi® (empagliflozin / linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies in the United States, including Walgreens and Rite help. GLYXAMBI, part of Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) diabetes alliance portfolio in the US and dual inhibitor combination therapy approved only the first combination of sodium glucose co-transporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase 4 (DPP-4) inhibitor activity structure in one tablet once daily.
When linagliptin empagliflozin and appropriate treatment, GLYXAMBI be approved, because the subsidiary dieting and execution (T2D) improved glycemic control in adults with type 2 diabetes. GLYXAMBI is a combination of 10 mg or 25 empagliflozin mg of a tablet once daily in the morning to take A SGLT2 inhibitor, and 5 linagliptin mg, DPP-4 inhibitors. GLYXAMBI not for people who have type 1 diabetes or diabetic ketoacidosis (an increase in blood or urine ketones). If you have pancreatitis (inflammation of the pancreas) do not know whether you have a higher chance of getting pancreatitis while taking GLYXAMBI.
"In accordance with its recent FDA approval of rapid market GLYXAMBI availability in late January is a reflection of Boehringer Ingelheim, and to bring new treatment options for Lilly's commitment to people with type 2 diabetes," in the United States Kateleen Dowd, senior vice president, marketing, Boehringer Ingelheim Pharmaceuticals, Inc., said, "As the fourth diabetes medicine emerged from our alliance pathway, we believe GLYXAMBI may help with low adult type 2 diabetes manage their blood sugar and their diabetes. "
GLYXAMBI savings card program is conducted online and in many doctors offices qualified patients. For terms and conditions, and any questions about the suitability or benefits, please visit GLYXAMBIsavings.com or call 1-855-GLYXAMBI (1-855-459-9262).
Should not be taken GLYXAMBI, if you have severe kidney problems, dialysis or, if you are allergic to empagliflozin and linagliptin or any of the ingredients in GLYXAMBI. Symptoms of a serious allergic reaction may include GLYXAMBI rash, itching, flaking or peeling; in your skin (items) are raised red patches; difficulty swallowing or breathing; difficulty breathing or swallowing may cause or your face, lips, tongue and throat swelling. If you have any of these symptoms, stop taking GLYXAMBI and tell your doctor immediately or go to the emergency room this room.
"As an additional program for metformin, GLYXAMBI is superior in reducing A1C and compare or alone or empagliflozin linagliptin", Lilly Diabetes, said David Kendall, MD, vice president, medical things. "The second type of diabetes management requires an individualized treatment plan and GLYXAMBI provide patients and their physicians with a new option to help improve blood sugar control."
The US Food and Drug Administration approval in the assessment basis Phase III clinical trial of the efficacy and safety of GLYXAMBI on (10/5 mg and 25/5 mg) to compare their elements empagliflozin (10 mg or 25 mg) or linagliptin (5 mg ) in adults with T2D also take high doses of metformin (mean dose of 1889 mg daily). Study, randomization with T2D and hemoglobin A1C (average blood glucose assessment of 686 adults in the past two to three-month period) between 7.0 and 10.5%, check for changes in A1C from drafted at 24 weeks. Research shows superior A1C reduction and GLYXAMBI empagliflozin or linagliptin compare their features. From an average of about 8.0 percent beginning drafted in this spreadsheet adults, respectively, 6.9 and 6.7% of the average A1C and GLYXAMBI 10/5 and 25/5 mg comparing 7.3 mg and 25 mg and 7.4%, respectively, and linagliptin 5 mg 7.3% of the average A1C empagliflozin 10 mg.
Published in Diabetes Care recent data shows that 58% and 62% take of GLYXAMBI 10/5 or 25/5 mg mg patients, in addition to metformin reached less than about 8% A1C from the drafting of 7% A1C, compare taken empagliflozin 10 mg of 28% of the patients, 33% take empagliflozin 25 mg and take linagliptin 5 mg of 36% each.
By 52 weeks, GLYXAMBI safety contour analysis of a merger has been demonstrated, and the most common response was the opposite urinary tract infection (UTI) (12.5% and 11.4% GLYXAMBI 10/5 mg and 25/5 mg, respectively; by 52 weeks, no patients discontinued due GLYXAMBI UTIs), nasopharyngitis (5.9% and 6.6% GLYXAMBI 10/5 mg and 25/5 mg, respectively) and upper respiratory tract infection (7.0% GLYXAMBI 10/5 mg and 25 / 5 mg).
Serious side effects may occur in taking GLYXAMBI, including the pancreas (pancreatitis) inflammation person, can be severe and result in death. Before you start taking GLYXAMBI, please tell your doctor if you have a history of pancreatitis, gallstones, alcoholism, or high triglyceride levels. Please stop taking GLYXAMBI and immediately tell your doctor if you have pain is severe and will not go away your stomach area (abdomen). Pain may feel to your return from your belly to. Pain may happen with or without vomiting. These may be symptoms of pancreatitis.
What is GLYXAMBI?
GLYXAMBI containing 2 diabetes medicine, empagliflozin and linagliptin prescription medicine. When dealing with empagliflozin and linagliptin is the appropriate time, GLYXAMBI diet and can be used as well as the implementation of lower blood sugar in adults with type 2 diabetes. |
国际免费电话：